JPMorgan Amends Regeneron Stake; Passive Ownership Update

Ticker: REGN · Form: SC 13G/A · Filed: 2024-01-25T00:00:00.000Z

Sentiment: neutral

Topics: institutional-ownership, amendment, passive-investing

TL;DR

**JPMorgan updated its Regeneron stake, signaling a portfolio rebalance.**

AI Summary

JPMorgan Chase & Co. filed an amended Schedule 13G/A on January 25, 2024, indicating a change in its beneficial ownership of Regeneron Pharmaceuticals, Inc. common stock as of December 29, 2023. This update, filed under Rule 13d-1(b), means JPMorgan Chase & Co. is a passive institutional investor and has adjusted its reported stake in Regeneron. For investors, this filing provides transparency into a major financial institution's holdings, signaling a potential shift in their confidence or portfolio allocation regarding Regeneron stock.

Why It Matters

This filing shows a major institutional investor, JPMorgan Chase & Co., has updated its position in Regeneron, which can influence market perception and trading activity.

Risk Assessment

Risk Level: low — This is a routine update from a passive institutional investor and does not indicate any immediate negative or positive operational risk for Regeneron.

Analyst Insight

Investors should note that JPMorgan Chase & Co. is a passive investor in Regeneron, meaning this filing reflects a portfolio adjustment rather than an attempt to influence company management. While the specific change in ownership percentage isn't detailed in this excerpt, the amendment suggests a re-evaluation of their position. Smart investors might monitor subsequent filings for the exact change in share count and consider if other large institutions are making similar adjustments, which could signal broader market sentiment for Regeneron.

Key Players & Entities

FAQ

What type of filing is this and what does 'A' signify?

This is an SC 13G/A filing. The 'A' signifies that it is an amendment to a previously filed Schedule 13G, indicating a change in the information provided in the prior filing.

Who is the 'Subject Company' in this filing?

The 'Subject Company' is REGENERON PHARMACEUTICALS, INC., identified by CIK 0000872589 and CUSIP 75886F107.

Who is the 'Filed By' entity in this document?

The 'Filed By' entity is JPMORGAN CHASE & CO., identified by CIK 0000019617.

What was the 'Date of Event Which Requires Filing of this Statement'?

The 'Date of Event Which Requires Filing of this Statement' was December 29, 2023.

Under which specific rule was this Schedule 13G filed?

This Schedule 13G was filed under Rule 13d-1(b), which typically applies to institutional investors who acquire beneficial ownership of more than 5% of a class of a company's equity securities with a passive investment intent.

From the Filing

0000019617-24-000143.txt : 20240125 0000019617-24-000143.hdr.sgml : 20240125 20240125111047 ACCESSION NUMBER: 0000019617-24-000143 CONFORMED SUBMISSION TYPE: SC 13G/A CONFIRMING COPY: PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240125 DATE AS OF CHANGE: 20240125 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-41938 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: JPMORGAN CHASE & CO CENTRAL INDEX KEY: 0000019617 STANDARD INDUSTRIAL CLASSIFICATION: NATIONAL COMMERCIAL BANKS [6021] ORGANIZATION NAME: 02 Finance IRS NUMBER: 132624428 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 383 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2122706000 MAIL ADDRESS: STREET 1: 383 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: J P MORGAN CHASE & CO DATE OF NAME CHANGE: 20010102 FORMER COMPANY: FORMER CONFORMED NAME: CHASE MANHATTAN CORP /DE/ DATE OF NAME CHANGE: 19960402 FORMER COMPANY: FORMER CONFORMED NAME: CHEMICAL BANKING CORP DATE OF NAME CHANGE: 19920703 SC 13G/A 1 REGENERON_PHARMACEUTICALS_.htm FILING REGENERON PHARMACEUTICALS, INC. Schedule 13G   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No. 01 )*   REGENERON PHARMACEUTICALS, INC.   (Name of Issuer)   Common Stock - par value $.001 per share (Title of Class of Securities)   75886F107 (CUSIP Number)   December 29, 2023 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:        x  Rule 13d-1(b)        o  Rule 13d-1(c)        o  Rule 13d-1(d)   * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.   The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).           CUSIP No.  75886F107                           1   NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)   JPMORGAN CHASE & CO. 13-2624428       2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)   (a)   o   (b)   o       3   SEC USE ONLY               4   CITIZENSHIP OR PLACE OF ORGANIZATION       Delaware         NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:  5   SOLE VOTING POWER       6,521,043       6   SHARED VOTING POWER       25,308 &#160

View on Read The Filing